VANCOUVER, BC / ACCESSWIRE / September 28, 2015 / The Mining Recruitment Group Ltd (MRG) is pleased to announce the launch of MININGRECRUITER, a wholly entity which is bringing mining recruitment into the 21st century.

With the launch of MiningRecruiter your team can now access the experience and talent network of a global mining recruitment leader for a FRACTION of the cost of a typical recruitment firm.

Andrew Pollard, President of MRG “The fact is, in the current market, mining companies don’t need all of the services provided by recruitment companies for the majority of searches. Recruiters are expensive and for many roles, candidates are abundant and eager. That being said, miners are now operating leaner than they have ever before and management teams are struggling to do more work with less resources. Your time is at a premium, yet when hiring is needed, you need to be assured you are exposed to the best mining talent in the marketplace. We started MiningRecruiter to be in the business of time and talent.”

Unlike any mining recruitment agency on the planet, our only focus is on handling the initial aspects of searches for mining employers: job description creation, targeted recruitment advertising campaigns(job boards/social media), and direct candidate outreach that is leveraged off of our network of mining professionals gleaned from 10+ years of international mining search. From that, we curate our list of top mining candidates from the response generated and provide it to our Clients who then see the process forward.

Andrew Pollard: “We handle the aspects of recruitment that require the most amount of time and expertise, the recruiting, leaving you to focus on the things that really matter, your company. The best part is, our model allows us to come in at a fraction of the cost versus a typical recruitment agency.”

We do the filtering upfront for Geologists, Mining Engineers, Investor Relations, and Management level mining positions, saving our clients significant time while having the most important aspect of the process guided by experience mining recruiters.

Unlike a recruitment agency, we aren’t commission based and don’t make placements. Our fee structure is upfront and transparent. There are no surprises; you engage us to coordinate recruitment marketing efforts(job boards, social media, referral network), strategically source and approach passive candidates, curating responses down to ensure you are only seeing the best of the best. We do the hard work for you and leverage our decade of experience in Mining Recruitment to attract the best.

Mining professionals looking for work or that are open to new opportunities are encouraged to create your free profile so we can reach out to you directly if suitable openings come available.

Employers wanting to learn more about our service, are requested to fill in the form on our website to have a representative contact you. We are also available at info@miningrecruiter.com

Journalists interested in scheduling an interview with Andrew Pollard please email info@miningrecruitmentgroup.com

SOURCE: MiningRecruiter.com

ReleaseID: 432247

NEW YORK, NY / ACCESSWIRE / September 28, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (OTCQB: TPIV).

The note is available here: TPIV Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

“We expect TPIV to use the proceeds for general corporate purposes and to prepare initial Proof of Concept Phase II clinical studies in triple negative breast and ovarian cancer patients beginning the second half of 2015. Management has stated that the design of the proof of concept clinical studies will complement the clinical trial planned at Mayo Clinic following its $13.3mn grant from the Department of Defense. We are maintaining our 12-month price target of $6.97 per share” stated Ajay Tandon, Chief Executive Officer of SeeThruEquity.

Additional highlights of the note are as follows:

Department of Defense grant to cover costs of Phase II

On September 15, 2015, TPIV reported that the Mayo Clinic – a collaborative research partner with the company – had been awarded a grant of $13.3mn from the U.S. Department of Defense. The announcement is material for TPIV, as the grant commences immediately and will fully cover the cost of a 280 patient Phase II Clinical Trial of TPIV’s Folate Receptor Alpha Vaccine in patients with Triple Negative Breast Cancer. TPIV has the commercial rights to the vaccine, following a recent licensing agreement with The Mayo Clinic, which has potential therapeutic applications for ovarian cancer, breast cancer, endometrial cancer and non-small cell lung cancer.

Recent $4.9mn financing provides flexibility for TPIV

TPIV has made substantial progress on its balance sheet over the last several months, culminating in the exercise of 16.7mn Series B and Series B-1 warrants from August 19, 2015 to September 9, 2015. The exercise of these warrants took place at a strike price of $0.20 per share, and adds $4.9mn in new cash to TPIV’s balance sheet. Adjusting for the 2Q15 ending cash balance of $3.1mn, TPIV has access to an adjusted $8.0mn in cash on hand. TPIV will also benefit indirectly from the $13.3mn grant to The Mayo Clinic, as the company will have access to the data for Phase II the Clinical Trial, controls the IND application, and has commercial rights to the Folate Receptor Alpha Vaccine for patients with Triple Negative Breast Cancer being studied in the trial. While acknowledging that the warrant exercise price is well-below recent market prices and the price target, we note that TPIV has been operating with a going concern qualification from its auditors, Marcum LLP, and the transaction substantially eases liquidity pressure on TPIV while it pursues its clinical pathway.

Please review important disclosures on our website at www.seethruequity.com.

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company’s peptide or nucleic acid-based immunotherapeutics comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient’s killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website at http://www.tapimmune.com for details.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:
Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 432253

NEW YORK, NY / ACCESSWIRE / September 17, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it recently initiated coverage of ROI Land Investments, Ltd. (OTCQB: ROII) with a 12 month price target of $4.52.

The report is available here: ROII Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Headquartered in Montreal, Canada, ROII is focused on early stage land development for residential real estate. Led by an experienced management team of established and well-connected real estate executives, ROII is focused on pre-development and entitlement approval of land – a targeted and potentially highly profitable area of residential real estate. ROII specializes in identifying and purchasing attractive vacant land in high growth areas according to strict analytical criteria. The company then enhances the land’s value through pre-development activity including managing the permitting and street-level infrastructure development of the land until it is construction-ready. Importantly, ROII is not a “land bank,” and seeks to reduce risk by developing quickly by working with local partners to reduce costs and arranging a clear exit strategy with homebuilders or corporates – the company’s deals have included large clients such as LNG Canada and partners such as Coast to Coast Holding in British Columbia and Baessler Homes in Colorado. In our view, ROII offers an intriguing equity-based conduit for a high risk, high potential reward investment in a key niche of the residential housing market.

“Anchored by large residential projects in Dubai, British Columbia, and Evans, CO, ROII has outlined ambitious development plans that leverage its industry knowledge and financing network in the United States, its home market of Canada, Europe and the Middle East. The projects are centered in six key regions and have the potential to create significant value for the company over the next 12-36 months if ROII can execute on the capital raising and operational goals outlined by management,” stated Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a 12-month price target of $4.52 per share.”

Additional highlights from the report are as follows:

Aggressive pipeline with potential for impact growth opportunities

ROII has outlined ambitious development plans focused in six key markets in the United States, its home market of Canada, and the GCC. The initial slate of projects has the potential to create significant value for the company over the next 12-36 months if management can execute on its capital raising and operational goals. The portfolio is anchored by a $100mn+ residential development play in Dubai in partnership with Sobha LLC, one of the largest and fully integrated developers in the region. ROII is developing three luxury apartment buildings in the middle of Sobha Hartland within Mohammed Bin Rashid Al Maktoum City, only minutes from the city center, comprising 300 units. ROII has already found a significant partner for its exit strategy, and expects to report material initial revenues from the project in 2016E.

Well-defined, focused process on a key residential real estate niche

ROII has assembled a well-defined, targeted strategy focused on land acquisition and early stage development of raw land for residential real estate developers. Specifically, the company operates in a four-step process: 1) Identify and acquire attractive land free of zoning restrictions; 2) Obtain the necessary permits and entitlements with local municipalities for residential pre-development; 3) Oversee outsourced development of technical and construction work to prepare residential lots and street infrastructure; and 4) Complete sale of subdivided land units or engage in a strategic partnership with large residential building developers. Importantly, as part of the decision to acquire new land, ROII management seeks large partners to secure a committed exit strategy if it is able to execute on developing the land through the permitting and infrastructure process. The company has already provided examples of this strategy, including a binding pre-sale arrangement with Baessler Homes, a well-respected local builder in Colorado, in which Baessler will acquire 1/3 of the company’s new development in Evans, Colorado.

Experienced management team

We see an experienced and well-connected management team as a critical factor for evaluating ROII, given the significant operational and capital raising hurdles that must be overcome for the company to meet its growth strategy. ROII’s management team has over 100 years of combined experience in real estate development, with over 1,000 lots developed in the last ten years and an extensive strategic contact network in the financial, construction, and real estate industries. Indeed, most recently, key members of ROII management founded and sold Azur Capital Fund LP, which management indicated was one of the fastest growing real estate lenders in Eastern Canada prior to its sale in 2014.

Initiate coverage with a price target of $4.52

Our analysis indicates a fair value estimate of $4.52 per share for ROII. If achieved, the target represents potential upside of 84.7% from the recent price of $2.20. We view ROII an intriguing equity-based conduit for a high risk, high potential reward investment in the residential housing market.

Please review important disclosures on our website at www.seethruequity.com.

About ROI Land Investments, Ltd.

ROI Land Investments, Ltd. (“ROI”) is a diversified real estate investment company specializing in land development. ROI’s business model consists of acquiring attractive land developments free of zoning restrictions, obtaining the necessary development permits, outsourcing the development of the infrastructure and profiting from the sale of the subdivided land units to known large regional developers.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 432264

LOS ANGELES, CA / ACCESSWIRE / September 28, 2015 / Medbox, Inc. (OTCQB: MDBX), a provider of specialized services to the cannabis sector, including operators of dispensaries, cultivation centers, manufacturers and research facilities in those states where approved, today announced it will provide specialized consulting services to the principals and operators of the Fweedom Collective medical dispensary on the opening of their second marijuana dispensary in the state of Washington.

The new 502 recreational retail dispensary will be located in Mountlake Terrace, Washington, and is scheduled to be operational by mid-2016. The agreement follows an earlier engagement under which Medbox is providing similar services to the principals of the Fweedom Collective for the opening of a dispensary in Mt. Vernon, WA, which is scheduled to be operational in the first half of 2016.

As with the Mt. Vernon property, Medbox will provide both pre- and post-opening services, including advising on regulatory compliance, security, training, IT and associated matters. Under the exclusive supervision and control of the Fweedom owners, the Mountlake Terrace dispensary also is expected to sell the new miVape personal vaporizer, which is produced by Medbox’s Vaporfection subsidiary.

“It is gratifying to have been selected for a second time by the principals of Fweedom, attesting to the solid relationship we are building,” said Jeff Goh, President and interim Chief Executive Officer of Medbox. “Both organizations have the same values for adhering to the highest standards of quality and professionalism.”

“We are off to an excellent start on our initial project in Mt. Vernon, and look forward to continuing to work closely with Medbox as we expand in Washington state, where marijuana has been approved both for medical and recreational use,” added J. Tyler Godfrey, one of the principals of Fweedom.

About Fweedom Collective

Founded in 2008 in Seattle, Fweedom, which currently operates a medical marijuana dispensary, started as a hemp alternative-based clothing company, bringing awareness to consumers of hemp and fabrics opposed to traditional cotton. The company evolved into a medical marijuana collective in 2011.

​About Medbox, Inc.

Medbox, Inc., a leader in the rapidly emerging cannabis sector, provides specialized services to operators of dispensaries, cultivation centers, manufacturers and research facilities in those states where approved. Through trusted clients and affiliates, the company promotes efficient, consistent, high quality products that are priced right, readily available and safely packaged. For more information about the company or to explore partnership, please visit www.medbox.com.

Forward-Looking Statements

Certain statements in this press release constitute forward-looking statements within the meaning of federal securities laws. Such statements, including, but not limited to, the timing of the opening of the new Mountlake Terrace dispensary, are based on current beliefs and expectations and are inherently subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the company’s control. In addition, certain forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Potential risks and uncertainties also include, but are not limited to, regulatory developments in the industry, as well as political and economic conditions present within the industry. For a more detailed description of the risk factors associated with the company, please refer to the company’s latest Annual Report on Form 10-K, and in particular, the section entitled “Risk Factors” therein, and in other periodic reports the company files with the Securities and Exchange Commission thereafter. The company does not assume any obligation to update any forward-looking statement to reflect events or developments after a forward-looking statement was made, unless required by law.

For more information, contact:

Janet Simmons
PondelWilkinson Inc.
310-279-5980
pwinvestor@pondel.com

SOURCE: Medbox, Inc.

ReleaseID: 432263

BEND, OR / ACCESSWIRE / September 28, 2015 / Med-Cannabis Pharma, Inc. (PINKSHEETS: MCPI) a publicly-traded company focused on becoming the market leader in marijuana retail distribution, cultivation, and infused products in the emerging legal cannabis industry to begin early adult recreational retail sales in Oregon.

Beginning on October 1, 2015, medical dispensaries in Oregon may sell one quarter of an ounce of recreational marijuana to any adult over the age of 21. Although the state of Oregon has approved early adult recreational retail sales, city municipalities and counties have the option to decline and restrict adult recreational retail sales in their respective jurisdictions and many have chosen to do so.

“I am pleased to announce that all three of our dispensaries branded The Medication Station, will be participating in early adult recreational retail sales. The counties and cities where our stores are located have all been approved for early sales,” states Graciela Moreno, CEO of Med-Cannabis Pharma, Inc. “All our markets have expanded exponentially to include the adult recreational retail market, this is a huge opportunity and a major catalyst for our business.”

Graciela Moreno, will be a featured speaker on the upcoming online Cannabis Investor Webcast (www.cannawebcast.com) on October 8th, 2015 at 12:00 p.m. PDT or 3:00 p.m. EDT, where she will give a business overview and discuss the rollout of adult recreational retail sales.

The legal marijuana industry is among the fastest growing industries in Oregon. ArcView Market Research estimated sales of legal cannabis in Oregon totaled $54M in 2014. With the addition of adult recreational retail sales, we can assume ArcView Market Research estimates for Oregon will increase significantly year-over-year for 2015.

“With Oregon’s recreational marijuana market opening in less than one week, Med-Cannabis Pharma, Inc. is poised to see significant top-line growth on a quarter-over-quarter basis. Technical420 has initiated coverage on MCPI and we will be monitoring how the company executes on this rapidly growing market,” states Michael Berger, Founder of Technical420 Research Firm. “Currently, MCPI has three Oregon dispensaries which are operational and branded under the name The Medication Station. Recent share price weakness coupled with improving financials has put MCPI on our radar.”

About Med-Cannabis Pharma, Inc.

Med-Cannabis Pharma, Inc. (PINKSHEETS: MCPI) is a publicly-traded company focused on marijuana retail distribution, cultivation, and infused products in the emerging legal cannabis industry by investing in strategic asset growth through evaluating, financing, and purchasing.

With our core business of product development and market expansion in the growing cannabis and hemp industry, we invest in early-stage fully licensed marijuana companies and facilities that display solid growth potential, and are continuing to independently pursue licensing in states where marijuana is legal.

The Company recognizes that its product is believed to improve the quality of life of individuals suffering from certain medical conditions. Med-Cannabis Pharma, Inc. intends to best serve the community with the safest and highest quality products while maintaining a high degree of transparency, control, and compliance to preserve its assets, foster growth, and add long-term value to shareholders.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. The Company does not undertake any duty nor does it intend to update the results of these forward-looking statements.

For more information please visit us at www.med-cannabispharma.com

Contact Information

GRACIELA MORENO
President
Med-Cannabis Pharma, Inc.
+1 214 666 8364

SOURCE: Med-Cannabis Pharma, Inc.

ReleaseID: 432255

VANCOUVER, BC / ACCESSWIRE / September 28, 2015 / Kiska Metals Corporation (“Kiska” or the “Company”) announces that Mr. Bipin Ghelani has resigned from the board of directors. Kiska wishes to acknowledge and thank Mr. Ghelani for his contributions to the Company over the last several years.

About Kiska Metals Corporation:

Kiska Metals Corporation is a prospect generator company with a high quality portfolio of gold and copper projects throughout North America. Two of Kiska’s projects are currently held under option agreements with major mining companies that are sole-funding exploration. Kiska has several other gold and copper projects available for option-joint venture as well as an extensive royalty portfolio.

On behalf of Kiska Metals Corporation

“Grant Ewing”

Grant Ewing
President & CEO
TEL: 604.669.6660

Neither TSX Venture Exchange nor its Regulation Services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT:
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This News Release includes certain “forward-looking statements”. Other than statements of historical fact, all statements included in this release, including, without limitation, statements regarding future plans and objectives of Kiska Metals Corporation, are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Kiska’s expectations are the risks detailed herein and from time to time in the filings made by Kiska Metals Corporation with securities regulators. Those filings can be found on the Internet at

SOURCE: Kiska Metals Corporation

ReleaseID: 432251